Digestive system neuroendocrine tumor, grade 1/2
MONDO:0000386A well-differentiated neuroendocrine tumor arising from the digestive system. It is characterized by the presence of cells with features similar to those of the normal endocrine cells of the digestive system. The neoplastic cells express immunohistochemical evidence of neuroendocrine differentiation and hormones. There is mild to moderate nuclear atypia and less than 20 mitoses per 10 HPF. It includes well-differentiated endocrine tumors or carcinoid tumors and well-differentiated endocrine carcinomas.
Also known as: alimentary part of gastrointestinal system neuroendocrine tumor, alimentary part of gastrointestinal system neuroendocrine tumour, digestive system NET, digestive system neuroendocrine tumor, digestive system neuroendocrine tumour, digestive system well differentiated neuroendocrine tumor, digestive system well differentiated neuroendocrine tumour, gastroenteropancreatic NET
1607 clinical trials for this condition and its sub-types, 66 tagged with Digestive system neuroendocrine tumor, grade 1/2 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Digestive system neuroendocrine tumor, grade 1/2
-
Pancreatic neuroendocrine tumor 60 trials · 77 incl. sub-types
11 sub-types
- Functional pancreatic neuroendocrine tumor 1 trial · 14 incl. sub-types Sub-types →
- Pancreatic insulin-producing neuroendocrine tumor 0 trials · 13 incl. sub-types Sub-types →
- Somatostatinoma 6 trials
- Pancreatic neuroendocrine tumor G1 1 trial · 5 incl. sub-types Sub-types →
- Non-functional pancreatic neuroendocrine tumor 4 trials Sub-types →
- Glucagonoma 2 trials
- Pancreatic gastrin-producing neuroendocrine tumor 2 trials Sub-types →
- PPoma 1 trial
- VIPoma 1 trial Sub-types →
- GRFoma 0 trials
- Pancreatic delta cell neuroendocrine tumor 0 trials Sub-types →
-
Small intestine neuroendocrine tumor, well differentiated, low or intermediate grade 4 trials · 9 incl. sub-types
6 sub-types
- Small intestinal neuroendocrine tumor G1 3 trials · 5 incl. sub-types Sub-types →
- Ileal neuroendocrine tumor, well differentiated, low or intermediate grade 0 trials · 3 incl. sub-types Sub-types →
- Duodenal neuroendocrine tumor, well differentiated, low or intermediate grade 0 trials Sub-types →
- Jejunal neuroendocrine tumor, well differentiated, low or intermediate grade 0 trials Sub-types →
- Small intestinal L-cell glucagon-like peptide producing tumor 0 trials
- Small intestinal vasoactive intestinal peptide producing tumor 0 trials
-
Intestinal neuroendocrine tumor G1 5 trials · 8 incl. sub-types
2 sub-types
- Small intestinal neuroendocrine tumor G1 3 trials · 5 incl. sub-types Sub-types →
- Colorectal neuroendocrine tumor G1 1 trial · 4 incl. sub-types Sub-types →
-
Neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor 0 trials · 5 incl. sub-types
3 sub-types
- Colon neuroendocrine tumor G1 1 trial · 3 incl. sub-types Sub-types →
- Neuroendocrine tumor of the appendix, well differentiated, low or intermediate grade 0 trials · 2 incl. sub-types Sub-types →
- Colonic L-cell glucagon-like peptide producing tumor 0 trials Sub-types →
-
Rectal neuroendocrine tumor 3 trials · 4 incl. sub-types
2 sub-types
- Rectal neuroendocrine tumor G1 1 trial
- Neuroendocrine tumor of the anal canal 0 trials
-
Gastric neuroendocrine tumor, well differentiated, low or intermediate grade 2 trials · 4 incl. sub-types
5 sub-types
-
3 sub-types
-
Esophageal neuroendocrine tumor 1 trial · 3 incl. sub-types
1 sub-type
-
2 sub-types
Most studied deeper sub-types
-
Promising cancer drug trial halted after just one patient
Disease control Stopped earlyThis study aimed to see if giving Lutathera (a radioactive drug) after surgery to remove liver metastases from neuroendocrine tumors could help keep the cancer from coming back. It planned to compare Lutathera plus best supportive care against best supportive care alone in about …
Phase 2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New 12-Week hormone therapy studied for rare tumors
Disease control Stopped earlyThis early-phase study tested a new formulation of octreotide (Debio 4126) that lasts 12 weeks, aiming to control hormone levels in people with acromegaly or certain neuroendocrine tumors. Only 19 participants were enrolled before the trial was terminated. The main goal was to me…
Phase 1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Swiss registry aims to map rare neuroendocrine tumors
Knowledge-focused Stopped earlyNeuroendocrine tumors of the gut and pancreas are rare and not well understood, which makes treatment decisions hard. The SwissNET registry collects health information from patients across Switzerland who have these tumors. Researchers will track tumor types, treatments used, and…
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC